Chong Kun Dang Pharmaceutical (185750) — Cash Flow-to-Debt Ratio
Chong Kun Dang Pharmaceutical (185750) has a Cash Flow-to-Debt Ratio of 0.02x as of March 2026, meaning its operating cash flow of ₩12.32 Billion could theoretically repay 0% of its total liabilities (₩803.02 Billion) in one year. See 185750 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Chong Kun Dang Pharmaceutical Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Chong Kun Dang Pharmaceutical across 10 annual periods. For the full cash flow conversion analysis, see how efficiently does Chong Kun Dang Pharmaceutical generate cash.
Annual Cash Flow-to-Debt Ratio for Chong Kun Dang Pharmaceutical (2016–2025)
Year-by-year debt coverage analysis for Chong Kun Dang Pharmaceutical. Check Chong Kun Dang Pharmaceutical (185750) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | ₩67.36 Billion | ₩793.94 Billion | ▼ -25.8% |
| 2024 | 0.11x | ₩64.29 Billion | ₩562.39 Billion | ▼ -78.9% |
| 2023 | 0.54x | ₩318.16 Billion | ₩586.79 Billion | ▲ +303.1% |
| 2022 | 0.13x | ₩67.73 Billion | ₩503.59 Billion | ▲ +401.3% |
| 2021 | 0.03x | ₩12.90 Billion | ₩480.89 Billion | ▼ -89.8% |
| 2020 | 0.26x | ₩104.32 Billion | ₩394.74 Billion | ▲ +11.6% |
| 2019 | 0.24x | ₩77.29 Billion | ₩326.40 Billion | ▲ +55.9% |
| 2018 | 0.15x | ₩42.63 Billion | ₩280.60 Billion | ▼ -49.1% |
| 2017 | 0.30x | ₩81.67 Billion | ₩273.91 Billion | ▲ +48.3% |
| 2016 | 0.20x | ₩57.79 Billion | ₩287.45 Billion | — |